Cian Healthcare Ltd
Incorporated in 2003, Cian Healthcare Ltd is engaged in manufacturing and marketing of pharmaceutical products.[1]
- Market Cap ₹ 59.6 Cr.
- Current Price ₹ 23.8
- High / Low ₹ 27.8 / 16.0
- Stock P/E 238
- Book Value ₹ 23.1
- Dividend Yield 0.00 %
- ROCE 4.94 %
- ROE 0.43 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.03 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -22.5%
- Promoter holding is low: 27.1%
- Company has a low return on equity of -1.91% over last 3 years.
- Promoters have pledged 47.8% of their holding.
- Company has high debtors of 155 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
57.09 | 73.73 | 77.87 | 68.59 | 61.70 | |
49.74 | 61.74 | 73.52 | 55.60 | 50.83 | |
Operating Profit | 7.35 | 11.99 | 4.35 | 12.99 | 10.87 |
OPM % | 12.87% | 16.26% | 5.59% | 18.94% | 17.62% |
0.79 | 0.07 | 0.47 | 0.73 | 0.44 | |
Interest | 7.22 | 7.92 | 6.55 | 6.30 | 5.79 |
Depreciation | 4.45 | 3.45 | 4.27 | 5.43 | 5.47 |
Profit before tax | -3.53 | 0.69 | -6.00 | 1.99 | 0.05 |
Tax % | -7.37% | 91.30% | 7.83% | -2.01% | -400.00% |
-3.79 | 0.05 | -5.53 | 2.03 | 0.25 | |
EPS in Rs | -1.62 | 0.02 | -2.21 | 0.81 | 0.10 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -6% |
TTM: | -10% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 53% |
TTM: | -87% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -16% |
3 Years: | -1% |
1 Year: | -14% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -2% |
Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 23.36 | 23.36 | 25.00 | 25.00 | 25.00 |
Reserves | 34.83 | 34.88 | 30.46 | 32.49 | 32.74 |
72.94 | 70.73 | 63.05 | 60.81 | 55.70 | |
25.41 | 28.28 | 47.42 | 42.18 | 47.74 | |
Total Liabilities | 156.54 | 157.25 | 165.93 | 160.48 | 161.18 |
39.43 | 36.54 | 49.58 | 44.59 | 39.28 | |
CWIP | 25.03 | 25.93 | 13.00 | 13.89 | 14.70 |
Investments | 4.89 | 4.89 | 4.89 | 4.89 | 4.89 |
87.19 | 89.89 | 98.46 | 97.11 | 102.31 | |
Total Assets | 156.54 | 157.25 | 165.93 | 160.48 | 161.18 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
-7.31 | 5.93 | 8.58 | 4.84 | ||
-27.44 | 2.71 | 1.40 | 2.55 | ||
35.78 | -9.78 | -10.96 | -7.41 | ||
Net Cash Flow | 1.03 | -1.13 | -0.98 | -0.01 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 127.80 | 93.56 | 125.24 | 139.58 | |
Inventory Days | 267.18 | 312.78 | 378.26 | 333.59 | |
Days Payable | 220.03 | 209.37 | 341.08 | 246.73 | |
Cash Conversion Cycle | 174.95 | 196.98 | 162.43 | 226.44 | |
Working Capital Days | 150.88 | 179.95 | 155.10 | 207.91 | |
ROCE % | 6.78% | 0.50% | 6.91% |
Documents
Announcements
- Intimation Of Receipt Of In-Principle Approval For Listing And Trading Equity Shares Of Company On BSE Main Board Platform. 5h
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 2d
-
Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)
24 Jun - Submission of Order of NCLT for Withdrawal of Case Titled Shreeji Pharmachem Vs Cian Healthcare Limited Having Case No. IA 3161 of 2024 in C.P. …
- Intimation Of Withdrawal Of Matter Admitted By National Company Law Tribunal (NCLT), Mumbai Bench. 21 Jun
-
Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)
21 Jun - Of Withdrawal of matter admitted by National Company Law Tribunal, Mumbai bench.
Business Overview:[1][2]
CHI is a fully integrated pharmaceutical company dealing in gynecology, hematinic, cardio-diabetic, orthopedic, pediatric, derma-cosmetic, antibiotic, CNS, vitamins & nutrient products.